Total Biologic capable providing unrivaled flexibility with multiple processing protocols and minimal sterile barrier entries
EmCyte's PurePRP™ (GS30 Pure II, AB60 Pure and GS120 Pure II) kits are the only Platelet Rich Plasma system that gives you the multiple processing protocols necessary to provide clinically effective PRP.See Our Product CatalogSee Our PRP Brochure
Process PurePRP™ without visible red blood cells or neutrophil granulocytes, making it the only non inflammatory PRP available. This protocol also has low viscosity for better tissue disbursement.
Process PurePRP with low red blood cell counts and enriched phagocytic power of neutrophil granulocytes are needed. This protocol produces the highest level of leukocyte chemotaxis, producing temporary inflammation, for antimicrobial phagocytosis and tissue regeneration. Once the neutrophil granulocytes have completed phagocytosis, they become apoptotic cells and are subsequently removed, thereby also eliminating the inflammatory activity.
PurePRP is exceptionally unique in that it can be prepared within a special autologous scope that allows the acidity to be completely removed without buffers or calcium activators, leaving you with PRP that is perfectly tolerated by patients.
Apply a powerful dose of PurePRP in low volume samples. Larger volumes (5-10mL) are generally not needed for small places. PurePRP allows you to concentrate the PRP volumes as low as 2mL without losing platelets or growth factors. This allows physicians to maintain a powerful clinical dose of PRP for the most minute of applications. Patients are guaranteed to receive the most effective dose of PRP regardless of the requirement.
The cellular biology of PurePRP® is ideal. Based on the independent data done by Principle Investigator Robert Mandle, PhD Biosciences Research Associates, Cambridge, MA, the evaluation of the cellular composition and structure of PurePRP® showed the following key points.
The PurePRP® II 2015 device produced a reduced Red Blood Cells PRP product with, on average, to 100 x 106 RCB/ml and an average hematocrit of 1.1%. Only 2% of the granulocytes were retained, a reduction of 84% from the baseline whole blood values. The PurePRP® II 2015 products had higher cell concentration and calculated cell metrics including platelet yield and concentration, RBC, mononuclear and granulocyte cell recoveries.
Only the PurePRP® II 2015 platform was capable of providing a PRP product with an optimum platelet concentration of > 1 x 106 platelets per µL (Giusti I, Rughetti A, D'Ascenzo S, et al. Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells. Transfusion 2009;49:771-8. Marx R, Garg A. Dental and craniofacial applications of platelet rich plasma. Carol Stream: Quintessence Publishing Co, Inc.; 2005)
Deliverable platelets are the actual volume of viable platelets contained in a PRP sample. PurePRP® provide upwards of 9 to 20 billion platelets in a 7mL sample of PurePRP® (significantly higher than its closest competitor). High volumes of deliverable platelets enhances the volumetric activity of platelet growth factors and cytokines. Platelet alpha granules contain various platelet growth factors that can promote tissue repair along with platelet cytokines that can provide the chemical stimulus needed to attract and direct regenerative cells to injured tissue. Deliverable platelets are significant in low application volumes.
Neutrophils are the most abundant leukocyte and one of the first-responders to migrate towards a site of injury or infection (chemotaxis). Neutrophils are also the hallmark of acute inflammation. This is an aggressive response of chemical signals from cytokines such as interleukins (IL-1, IL-8) and tumour necrosis factor alpha (TNF-α) along with many others. The primary function of the neutrophil is to engulf and destroy foreign material through phagocytosis. Under normal circumstances, neutrophils are short lived (1-2 days) and are cleared by tissue macrophages. In conditions where the neutrophils cannot be cleared, they undergo a process called necrosis resulting in the release of all of the intracellular contents. This causes the amplification and prolonging of the inflammatory response. This prolonged amplified inflammatory response potential raises concern for many practitioners.
Monocytes are the largest of all leukocytes and are characteristically non-inflammatory phagocytic cells. Monocytes migrate to sites of injury and infection and differentiate into macrophages and dendritic cells to elicit an immune response which last for longer periods of time (months rather than days when compared to neutrophils). Monocytes illicit the immune response through phagocytosis, antigen presentation, and cytokine production each of which has a specific and deliberate function in enhancing the immune response through both protective prophylaxis and active phagocytosis.
PurePRP® is unique in that it greatly enhances monocyte concentrations, while giving the end user control over the amount of neutrophils they would like to add to their PRP preparation. PurePRP® takes advantage of the long term phagocytic and protective properties of the monocytes while avoiding the potential harmful inflammation incurred by large concentrations of neutrophils that go through cellular necrosis. Another differentiating factor that help to explain the natural success of PurePRP®.